ACON icon

Aclarion

7.20 USD
-0.19
2.57%
At close Jul 11, 4:00 PM EDT
1 day
-2.57%
5 days
-3.61%
1 month
-6.37%
3 months
-13.57%
6 months
-99.27%
Year to date
-99.44%
1 year
-99.75%
5 years
-100.00%
10 years
-100.00%
 

About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Employees: 6

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

4.42% less ownership

Funds ownership: 4.43% [Q4 2024] → 0.01% (-4.42%) [Q1 2025]

44% less funds holding

Funds holding: 9 [Q4 2024] → 5 (-4) [Q1 2025]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

99% less capital invested

Capital invested by funds: $66.4K [Q4 2024] → $723 (-$65.7K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for ACON.

Financial journalist opinion

Based on 4 articles about ACON published over the past 30 days

Neutral
MCAP MediaWire
4 days ago
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 – PRISM MediaWire – Aclarion, Inc.
Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
Neutral
MCAP MediaWire
2 weeks ago
First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial
BROOMFIELD, Colo., June 25, 2025 – PRISM MediaWire – Aclarion, Inc.
First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial
Neutral
GlobeNewsWire
2 weeks ago
First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY expected in Q2 2026 BROOMFIELD, Colo., June 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial evaluating Nociscan's clinical and economic value in spine surgery.
First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial
Neutral
GlobeNewsWire
2 weeks ago
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of Spine Surgery Think Tank, taking place in Cabo San Lucas, June 25-28, 2025.
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
Neutral
MCAP MediaWire
1 month ago
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
BROOMFIELD, Colo., June 10, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of UHealth — University of Miami Health System and the University of Miami Miler School of Medicine as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site. The landmark CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
Neutral
GlobeNewsWire
1 month ago
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
Neutral
GlobeNewsWire
1 month ago
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Neutral
MCAP MediaWire
2 months ago
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Press Audio: BROOMFIELD, Colo., May 05, 2025 – PRISM MediaWire – Aclarion, Inc.
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Neutral
GlobeNewsWire
2 months ago
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Neutral
GlobeNewsWire
2 months ago
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries   BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc.,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Charts implemented using Lightweight Charts™